Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Crispr therapeutics ag save search
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Published: 2024-04-22 (Crawled : 21:00) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 0.49%
H: 4.9%
C: 0.86%
crispr presentation cell meeting therapeutics therapy
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -2.41%
H: 0.23%
C: -0.03%
crispr cell meeting therapeutics therapy
CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research
Published: 2023-05-05 (Crawled : 09:00) - biospace.com/
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 1.88%
H: 6.97%
C: 3.09%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.08%
H: 1.89%
C: 1.35%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.33%
H: 1.88%
C: 1.66%
west pharmaceuticals research therapy
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)
Published: 2022-09-28 (Crawled : 13:20) - biospace.com/
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 0.83%
H: 5.1%
C: 4.33%
ctx130 treatment fda designation crispr lymphomas t-cell granted therapeutics therapy rmat
CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)
Published: 2022-02-02 (Crawled : 14:00) - biospace.com/
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 2.54%
H: 0.0%
C: 0.0%
treatment trial therapeutics crispr cel diabetes phase 1 therapy
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies
Published: 2021-11-22 (Crawled : 14:00) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -1.44%
H: 0.0%
C: 0.0%
ctx110 crispr treatment fda therapy granted therapeutics t-cell designation rmat
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes-Initiation of patient enrollment expected by year-end-
Published: 2021-11-16 (Crawled : 14:00) - biospace.com/
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -5.24%
H: 0.0%
C: 0.0%
crispr diabetes treatment therapy trial enroll
CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Published: 2021-10-01 (Crawled : 14:15) - biospace.com/
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -0.16%
H: 0.57%
C: -0.41%
crispr immunotherapy therapy cancer preclinical pre-clinical
Global Gene Therapy Market Report 2021: Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
Published: 2021-07-13 (Crawled : 11:00) - prnewswire.com
QURE | $4.57 -3.79% -3.94% 640K
|
Health Technology
|
| O: -0.64%
H: 1.28%
C: -1.0%
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: -0.88%
H: 1.98%
C: -1.13%
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: -0.49%
H: 1.63%
C: 0.0%
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -0.51%
H: 0.95%
C: -1.06%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 0.05%
H: 0.22%
C: -4.26%
NTLA | $21.16 -1.72% -1.75% 860K
|
Health Technology
|
| O: -0.48%
H: 1.36%
C: -2.65%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.35%
H: 1.01%
C: 0.27%
EDIT | News | $5.355 -1.92% -1.96% 1.6M
|
Health Technology
|
| O: -0.15%
H: 1.2%
C: -4.78%
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -0.47%
H: 0.76%
C: -3.24%
BLUE | $0.9274 -4.45% -4.66% 8.1M
|
Health Technology
|
| O: -0.7%
H: 0.95%
C: -2.43%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: -2.09%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: -0.56%
H: 1.51%
C: -0.23%
ADAP | $1.085 -4.83% -5.07% 780K
|
Health Technology
|
| O: -0.25%
H: 0.25%
C: -1.78%
ABEO | News | $3.165 -7.19% -7.74% 2.2M
|
Health Technology
|
| O: 2.11%
H: 0.0%
C: -4.83%
gene therapy therapy gene therapies
Global Gene Therapy Market to Reach $2.7 Billion by 2026
Published: 2021-06-29 (Crawled : 14:15) - prnewswire.com
QURE | $4.57 -3.79% -3.94% 640K
|
Health Technology
|
| O: 0.1%
H: 1.22%
C: -0.26%
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.25%
C: -2.43%
SGMO | News | $0.4911 -5.72% -6.07% 1.2M
|
Health Technology
|
| O: -0.91%
H: 1.08%
C: -2.66%
RGNX | $16.05 0.94% 0.93% 350K
|
Health Technology
|
| O: -0.26%
H: 1.59%
C: -1.13%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 1.13%
H: 0.1%
C: -8.26%
NTLA | $21.16 -1.72% -1.75% 860K
|
Health Technology
|
| O: -2.19%
H: 17.95%
C: 16.17%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.04%
H: 0.53%
C: 0.38%
EDIT | News | $5.355 -1.92% -1.96% 1.6M
|
Health Technology
|
| O: 2.07%
H: 3.99%
C: 2.67%
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -0.41%
H: 1.48%
C: -0.34%
BLUE | $0.9274 -4.45% -4.66% 8.1M
|
Health Technology
|
| O: -0.26%
H: 0.64%
C: -3.25%
AGTC | News | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 1.49%
H: 0.0%
C: -2.44%
ALNY | $143.8 -1.55% -1.58% 390K
|
Health Technology
|
| O: 0.42%
H: 0.15%
C: -0.62%
ADAP | $1.085 -4.83% -5.07% 780K
|
Health Technology
|
| O: -0.68%
H: 1.6%
C: 0.23%
ABEO | News | $3.165 -7.19% -7.74% 2.2M
|
Health Technology
|
| O: 0.0%
H: 0.59%
C: -2.96%
gene therapy therapy gene therapies market
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
Published: 2021-06-15 (Crawled : 12:00) - biospace.com/
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -0.38%
H: 0.0%
C: -3.63%
crispr collaboration sclerosis iot therapy friedreich's ataxia friedreich’s ataxia
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: -10.49%
H: 3.1%
C: -0.53%
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 4.42%
H: 0.63%
C: -1.69%
crispr treatment europe therapy ctx001
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
Published: 2021-05-12 (Crawled : 15:15) - globenewswire.com
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: -0.44%
H: 1.7%
C: 0.29%
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: -2.06%
H: 2.89%
C: -0.56%
crispr europe therapy ctx001
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
Published: 2020-12-14 (Crawled : 13:02) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 3.44%
H: 4.2%
C: -2.25%
crispr therapy hiv granted grant
CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine
Published: 2020-12-05 (Crawled : 18:00) - globenewswire.com
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
| Email alert
Add to watchlist
therapy crispr ctx001
CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Thalassemia
Published: 2020-12-01 (Crawled : 22:04) - globenewswire.com
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: -0.12%
H: 1.36%
C: 1.24%
CRSP | News 4 | $55.66 -1.33% -1.35% 910K
|
Health Technology
|
| O: 2.4%
H: 3.49%
C: -0.3%
therapy crispr disease ev ctx001
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.